Videos |View More
Video
Meet the Team: Rohit Gosain, MD
“I threw away my circuit board and replaced with a stethoscope because I felt I was missing that human connection,” says Dr. Gosain, who recently became the Medical Director for Roswell Park Hematology Oncology Southtowns, in Orchard Park, NY.
Video
Watch: When to Think of Amyloidosis, How to Diagnose and Treat
Experts from Roswell Park Comprehensive Cancer Center joined with colleagues from the Boston University School of Medicine to discuss the latest information on amyloidosis, including recommendations for physicians on how to diagnose the ...
Video
Meet the Team: Hamza Hassan, MD
Hamza Hassan, MD, thinks the future is bright for patients with Myeloma and Amyloidosis. With encouraging research and treatment development opportunities, he moved from Boston to Buffalo to join the team at Roswell Park Comprehensive ...
Video
First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park
Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers.
Symposium
This CME-accredited activity, the Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting, is a two-day symposium designed to provide an engaging and interactive forum for discussing the ...
Video
Meet the Team: Dr. Ehsan Malek
As the Director of the Multiple Myeloma Translational Research Program at Roswell Park, Dr. Malek brings with him a passion for finding new and innovative treatments for this disease and other plasma cell disorders
Video
Diagnosis and Co-management of Hematologic Malignancies for the Primary Care Provider
Our expert speakers dive into the latest techniques in diagnostics, treatment modalities, and interdisciplinary approaches, providing attendees with valuable insights to enhance patient care and outcomes.
Video
Updates and Advancements in Cellular Therapy at Roswell Park
Originally Broadcast: Thursday, November 9, 2023 6:00 - 7:30 PM EST - This program is intended for Hematologists, Oncologists, Pharmacists, Pathologists, and other healthcare professionals that care for cancer patients.
Symposium
The New York State Cellular Therapy Consortium
This is a clinically oriented educational program intended for hematologists, oncologists, pharmacists, pathologists, and other healthcare professionals that may diagnose, treat, or manage patients with cancer. The goal is to educate participants ...
News |View More
News
Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma
Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on multiple myeloma cells.
News
Inherited Changes in BRCA Genes Linked to Increased Risk of Multiple Myeloma
While multiple myeloma affects mostly older adults — 95% are over 50 Kenan Onel, MD, and his colleagues discovered that patients whose BRCA genes contained PGVs, which dramatically increase cancer risk, were more likely to be diagnosed ...
News
Congressman Kennedy Announces Over $7.7 Million for State-of-the-Art Biobank at Roswell Park
Congressman Kennedy announced $7,731,872 in funding for the Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of the National ...
News
The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML).
News
Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...
News
Next Generation Armored Car T-Cell Therapy Trial Now Open
This Phase I/II trial will test the effectiveness, safety, side effects, and best dose of CD19-targeted Chimeric Antigen Receptor (CAR) modified T cells genetically engineered to secrete interleukin 12 (IL-12) in patients with hematologic B-cell malignancies.
News
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
News
A team of researchers from Roswell Park Comprehensive Cancer Center, report that the efficacy of doxorubicin, a widely used chemotherapy drug, was enhanced in preclinical lymphoma models when it was combined with propranolol.
News
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical ...
This site is intended for healthcare professionals
Download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED